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2Abstract
T cell antigen receptor (TCR) signaling drives distinct responses depending upon the differentiation
state and context of CD8+ T cells. We hypothesized that access of signal-dependent transcription factors
(TFs) to enhancers is dynamically regulated to shape transcriptional responses to TCR signaling. We
found that the TF BACH2 restrains terminal differentiation to enable generation of long-lived memory
cells and protective immunity following viral infection. BACH2 was recruited to enhancers where it
limited expression of TCR-driven genes by attenuating the availability of activator protein 1 (AP-1) sites
to Jun family signal-dependent TFs. In naïve cells, this prevented TCR-driven induction of genes
associated with terminal differentiation. Upon effector differentiation, reduced expression of BACH2
and phosphorylation enabled unrestrained induction of TCR-driven effector programs.
3Introduction
Following infection or immunization, naïve CD8+ T cells undergo widespread transcriptional changes
that initiate burst-like clonal proliferation and differentiation to generate a population of effector cells
reactive against pathogen-associated antigens. Following resolution of infection, the majority of
responding T cells are eliminated, allowing brisk restoration of immune homeostasis. A fraction of cells
escape this fate and persist to contribute to immunological memory1-6. The presence of greater numbers
of antigen-specific memory cells enable more efficient pathogen clearance upon secondary infection.
Thus, dynamic regulation of T cell differentiation, proliferation and survival is required to generate and
then curtail effector responses while maintaining a subset of pathogen-specific memory cells following
withdrawal of antigen.
T cell antigen receptor (TCR) signaling is critical to both initiation and diversification of CD8+
T cell responses. Strong or repeated TCR signaling drives progressive changes in gene expression that
result in loss of lymphoid homing potential, acquisition of effector cell functions, and ultimately,
terminal effector differentiation and apoptosis7, 8. Memory cells differentiate in response to weak antigen
signals that are insufficient to drive full effector differentiation1, 5, 9. Consequently, memory cells
manifest only a subset of transcriptional changes accompanying effector differentiation and their
intermediate state of differentiation enables them to remain functionally quiescent, survive and circulate
among secondary lymphoid tissues where they can be efficiently recruited into secondary responses10-
12. TCR signaling not only plays a key role in diversification of CD8+ T cell responses, but induces
functionally distinct outcomes within diversified populations of CD8+ T cells. While TCR stimulation
of naïve cells predominantly results in proliferation and differentiation, stimulation of effector cells
drives rapid induction of effector cytokines and cytotoxic molecules while stimulation of terminally
differentiated effector cells induces apoptosis1, 8, 9.
AP-1 family TFs play a central role in transducing TCR-driven effector programs. AP-1 TFs,
including Jun (c-Jun, JunD, JunB), Fos (c-Fos, Fosb, Fosl1, Fosl2) and BATF (BATF1, BATF2,
BATF3) TFs, contain basic leucine-zipper (bZip) domains that enable them to form heterodimeric
complexes at palindromic 12-O-Tetradecanoylphorbol-13-acetate (TPA) response elements (TRE; 5'-
TGA(C/G)TCA-3')13, 14. Members of the Jun family of AP-1 TFs are phosphorylated in response to TCR
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differentiation where they predominantly activate gene expression15-20. High levels of c-Jun
phosphorylation are detected in interleukin 7 receptor-negative (IL-7R–) effector CD8+ T cells while low
levels of Jun phosphorylation are detected within long-lived IL-7R+ memory CD8+ T cells following
viral infection21. We hypothesized that modulation of the availability of AP-1 sites to Jun family TFs
allows TCR-driven effector differentiation programs to be modulated in a stage-specific and contextual
manner in CD8+ T cells.
BACH2 is a 92 kDa transcriptional repressor of the bZip TF family22. We have previously found
that BACH2 promotes the differentiation of Foxp3+ regulatory T (Treg) cells and that this function is
required for prevention of lethal inflammation23. In B cells, BACH2 is critical for somatic hypermutation
and class-switch recombination, and its absence leads to impaired generation of class-switched antibody
responses22, 24. BACH2, like AP-1 TFs, contains a bZip domain and binds to Maf recognition elements
(MARE) which embed a TRE sequence25. Silencing of Bach2 mRNA following activation of CD8+ T
cells results in reduced cellular persistence26. These observations led us to explore whether BACH2
controls CD8+ T cell differentiation in vivo by modulating the availability of enhancers to AP-1 family
signal-dependent TFs.
5Results
BACH2 is required for CD8+ T cell memory
Defective generation of Foxp3+ Treg cells in Bach2–/– mice results in unrestrained effector differentiation
among conventional T cells23. To evaluate the cell-intrinsic function of BACH2 in CD8+ T cells, we
reconstituted C57BL/6 mice with 1:1 mixtures of congenically distinct CD45.1+ wild-type (WT) and
Thy-1.1+ Bach2–/– mature lineage-depleted (Lin–) bone marrow (BM) cells (Supplementary Fig. 1a)
and evaluated CD8+ T cells in these animals. We observed diminished frequencies of both effector
(CD62L–) and central memory (CD62L+ CD44+) cells amongst Bach2–/– cells in the steady state,
suggesting a cell-intrinsic function of BACH2 in either the generation or maintenance of antigen-primed
CD8+ T cell responses (Supplementary Fig. 1b-c). We therefore sought to test whether BACH2
controls responses to defined antigens. We utilized an acute viral infection model wherein recombinant
vaccinia virus expressing chicken egg ovalbumin (VV-OVA) is recognized by minimal numbers of
adoptively transferred OT-I TCR-transgenic CD8+ T cells (hereinafter, OT-I) specific for the OVA257-
264 epitope. We obtained cells from mice reconstituted with mixtures of congenically distinct WT
CD45.1+ and Bach2–/– Thy-1.1+ OT-I transgenic BM and sorted naïve CD44– CD62L+ OT-I cells of both
genotypes from these animals. Naïve WT and Bach2–/– OT-I cells were co-transferred at a 1:1 ratio into
recipient C57BL/6 mice (Fig. 1a and Supplementary Fig. 1d) prior to infection with VV-OVA. In
response to viral infection, Bach2–/– CD8+ T cells exhibited impaired expansion and a near-complete
failure to establish long-lived memory responses (Fig. 1b,c). The reduced ratio of KO:WT cells found
in spleens of immunized animals was similar to that in the lungs and liver, but there was a further
reduction in the frequency of KO cells in the lymph nodes (Fig. 1d). Thus, BACH2 is required for
maintenance of CD8+ T cell responses following primary infection.
To test the function of BACH2 in mediating secondary protective immunity following primary
infection, we infected mice with a recombinant strain of Listeria monocytogenes expressing the OVA257-
264 epitope (LM-OVA) 60 days after individual transfer of normalized numbers of naïve WT or Bach2–
/– OT-I cells and primary infection with VV-OVA. Consistent with defective maintenance of Bach2–/–
CD8+ T cell responses, mice that had initially received Bach2–/– OT-I cells exhibited significant
impairment in their ability to clear LM-OVA compared with mice that had received WT cells (Fig. 1e).
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of WT and Bach2–/– central memory (CM; CD44+ CD62L+) or effector memory (EM; CD44+ CD62L-)
cells isolated at day 14 following primary infection into infection-naïve recipients and infected these
mice with VV-OVA. Notably, both Bach2–/– CM and EM cells exhibited defective secondary response
kinetics, although the defect was more striking amongst CM cells compared with EM cells (Fig. 1f-g).
Collectively, these findings indicate that BACH2 plays a non-redundant cell-autonomous role in the
maintenance of primary and secondary CD8+ T cell responses and generation of protective immunity
following primary viral infection.
BACH2 restrains terminal differentiation of CD8+ T cells
Progressive acquisition of effector characteristics is accompanied by loss of lymphoid homing potential
and reduction in cellular lifespan1, 7, 11. We asked whether defective maintenance and lymphoid homing
of Bach2–/– CD8+ T cells are accompanied by changes in their differentiation state. Amongst antigen-
experienced CD8+ T cells, CD62L+ cells comprise the central memory subset, CD62L– KLRG1– cells
comprise the effector subset and KLRG1+ cells comprise the terminally differentiated effector subset1.
We measured expression of CD62L and KLRG1 on adoptively transferred naïve WT and Bach2–/– OT-
I CD8+ T cells following viral infection. We observed excessive induction of terminally differentiated
KLRG1+ cells and a near-complete loss of CD62L+ Bach2–/– central memory cells as a ratio of surviving
cells at late timepoints following infection (Fig. 2a-d). However, the decline in total CD8+ T cell
numbers amongst Bach2–/– cells resulted in a decrease in the absolute number of terminally differentiated
effector cells (Supplementary Fig. 2a) in addition to memory cells. Consistent with augmented effector
differentiation of Bach2–/– cells, we noted higher expression of the effector cytokine interferon- (IFN-
) upon brief restimulation ex vivoFig. 2e). Conversely, retroviral overexpression of BACH2 in OT-I
CD8+ T cells prevented acquisition of terminally differentiated effector cell characteristics upon transfer
into mice subsequently infected with VV-OVA, as indicated by increased expression of CD62L and
lower expression of CD44 and KLRG1 (Fig. 2f). Additionally, cells transduced with BACH2 expressed
reduced amounts of the effector cytokines IFN- and tumor necrosis factor (TNF) (Fig. 2g).
7Terminal differentiation is associated with loss of memory precursor potential amongst effector
cells27. Accordingly, we noted a striking loss of CD127+ KLRG1– MPEC and an increase in the
frequency of CD127– KLRG1+ SLEC amongst Bach2–/– cells at day 7 following infection (Fig. 3a). We
also noted a reduction in the frequency of CD127+ cells within the CD62L– KLRG1– effector population
that predominates at day 7 (Supplementary Fig. 2b). We did not, however, observe differences in CD43
and CD27 expression (Supplementary Fig. 2c-d)28-30. Increased acquisition of effector cell
characteristics was also observed following stimulation of Bach2–/– CD8+ T cells in vitro and this was
antigen-dependent (Supplementary Fig. 3a), proliferation-independent (Supplementary Fig. 3b) and
associated with elevated expression of the lymphocyte activation markers CD25 and CD69
(Supplementary Fig. 3c).
Terminal differentiation of CD8+ T cells is accompanied by induction of apoptosis31, 32. We
measured rates of proliferation and apoptosis amongst WT and Bach2–/– CD8+ T cells responding to
viral infection. While BACH2 was dispensable for sustaining early proliferation (Fig. 3b), we observed
substantially increased rates of apoptosis amongst Bach2–/– cells at days 5, 7 and 10 post-infection (Fig.
3c), coinciding with the marked attrition in their cell numbers. Defective survival was not merely
attributable to induction of apoptosis at the naïve cell stage, since elevated levels of apoptosis were
observed at successive rounds of cell division following stimulation of Bach2–/– naïve CD8+ T cells in
vitro (Supplementary Fig. 3d). Terminal differentiation of CD8+ T cells is accompanied by depletion
of anti-apoptotic Bcl-2 family members27, 33, 34. We observed decreased expression of the anti-apoptotic
Bcl-2 family members Bcl-xL and Mcl1 within Bach2–/– in vitro activated cells (Supplementary Fig.
3e). Corresponding to widespread differences in their phenotype, RNA sequencing (RNA-Seq) analysis
of WT and Bach2–/– cells isolated at day 7 following acute infection revealed widespread differences in
gene expression (Supplementary Fig. 4a and Supplementary Table 1) and enriched in transcripts
associated with effector differentiation (Supplementary Fig. 4b and Supplementary Table 2). Gene
expression differences between WT and Bach2–/– cells persisted, though were substantially mitigated,
when fractionated populations of CD62L– KLRG1– effector cells were specifically analyzed
(Supplementary Fig. 4c and Supplementary Table 3). Thus, BACH2 prevents terminal effector
differentiation and apoptosis, enabling generation of long-lived memory cells following viral infection.
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AP-1 TFs bind to genomic TRE and play central roles in transducing TCR-driven effector programs.
We hypothesized that BACH2 restrains terminal effector differentiation by binding to TRE and
attenuating the activity of AP-1 factors. We mapped genome-wide BACH2 binding-sites using
chromatin immunoprecipitation coupled with massively parallel DNA sequencing (ChIP-Seq). To
generate sufficient numbers of cells required for ChIP, we stimulated naïve FACS-sorted CD8+ T cells
with plate-bound anti-CD3 and anti-CD28 antibodies in the presence of IL-2 for 2 days and harvested
cells after 3 further days of culture (hereinafter d5 in vitro activated CD8+ T cells). We observed
extensive binding of BACH2 at intergenic and intronic regions (Fig. 4a). Analysis of these sites enabled
identification of the BACH2 consensus motif in CD8+ T cells (5'-TGA(C/G)TCAGC-3') which
embedded the canonical AP-1 recognition motif (5'-TGA(C/G)TCA35) (Fig. 4b). Importantly, this
consensus motif was remarkably similar to the BACH2 recognition motif previously resolved using
PCR-assisted binding site selection in vitro25. Given that a majority of BACH2 binding sites were outside
annotated promoter regions, we next asked whether BACH2 binds to enhancers. We measured the
genome-wide distribution of the coactivator protein p300 and the histone modifications H3K27Ac and
H3K4me1, which are characteristically located at enhancers36. We found that a majority of BACH2
binding sites colocalized with one or more of these markers (Fig. 4c). Consistent with similarity in the
binding motifs of BACH2 and AP-1 factors, BACH2 binding sites were enriched at known genome-
wide binding sites of the AP-1 family members JunB, c-Jun and JunD (Fig. 4d-f and Supplementary
Tables 4-6)17.
Extensive colocalization of BACH2 at known AP-1 sites in CD8+ T cells led us to enquire
whether BACH2 functions to limit TCR-driven gene expression in CD8+ T cells. A prediction of this
hypothesis is that a majority of TCR-driven genes it represses will not be differentially expressed prior
to stimulation of Bach2–/– compared with WT cells. To test this, we measured global changes in gene
expression induced by brief (6h or 18h) ex vivo stimulation of naïve FACS-sorted WT and Bach2–/–
CD44– CD62L+ CD8+ T cells using RNA-Seq. Of 442 significantly upregulated genes in Bach2–/– cells
compared with WT cells at any timepoint before or after stimulation (0, 6 or 18h; FC>2; p<0.05; Fig.
95a), 192 TCR-driven genes (induced at either 6 or 18h compared with 0h following TCR stimulation in
either WT or Bach2–/– cells) were identified. Of these genes, a substantial majority (163 genes, 84%)
lacked significant differences in expression prior to stimulation (Fig. 5b,c and Supplementary Table
7). However, as early as 6 hours following stimulation, we observed increased induction of genes
encoding proteins associated with effector differentiation in Bach2–/– cells, including Ifng, Cd44, Ccl1,
Ccl9, Icam1, Lif, Lta, Gadd55b, Ttc39c. A majority (72.3%) of excessively induced genes contained
mapped BACH2 binding sites within 15 kb upstream and 3 kb downstream of their gene bodies, 
suggesting that BACH2 may directly repress their TCR-induced expression. The identified genes were
also strikingly positively enriched within the global transcriptional differences between terminally
differentiated KLRG1+ CD8+ T cells responding to VV-OVA infection and naïve CD8+ T cells (Fig. 5d,
Supplementary Table 8).
BACH2-mediated repression of TCR-driven gene expression is exemplified at the Ifng and
Gp49a loci (Fig. 5e), at which colocalization of BACH2 and AP-1 factors is observed at known37 or
putative regulatory elements (Fig. 5e). To test whether excessive TCR-induced gene expression in
Bach2–/– cells is driven by Jun family AP-1 factors, we utilized a well-characterized pharmacological
inhibitor (JNKi) of Jun N-terminal kinase (Jnk)38, which activates Jun family TFs in response to TCR
signaling39. Pretreatment with JNKi partially reversed excessive induction of Gp49a and Ifng mRNA
following stimulation of Bach2–/– naïve cells (Fig. 5f). Moreover, BACH2-mediated repression of TCR-
driven Gp49a and Ifng expression was dependent upon its basic leucine-zipper domain since suppression
of both genes resulting from BACH2 overexpression was abrogated when the bZip domain was
disrupted (Fig. 5g). Collectively, these results indicate that BACH2 restrains TCR-driven transcriptional
programs associated with terminal effector differentiation in naïve CD8+ T cells.
BACH2 limits access of Jun family TFs to AP-1 sites
We hypothesized that BACH2 represses TCR-driven gene expression by competing with AP-1 factors
for DNA binding. A prediction of this hypothesis is that loss of BACH2 will cause increased binding of
Jun family TFs at its binding sites. BACH2 is expressed at readily detectable levels within WT d5 in
vitro activated CD8+ T cells (Fig. 6a inset and Supplementary Fig. 5a). In vitro activated WT and
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Bach2–/–cells were briefly restimulated with platebound anti-CD3 for 2h and subjected to either ChIP-
Seq analysis of JunD binding or RNA-Seq analysis. Strikingly, loss of BACH2 resulted in increased
global binding of JunD at BACH2 binding sites (Fig. 6a) despite similar levels of total JunD in these
cells (Fig. 6a, inset). Increased JunD enrichment was restricted to shared JunD-BACH2 sites since
average JunD binding was not significantly increased at JunD sites where BACH2 does not bind
(Supplementary Fig. 5b). A small proportion of JunD binding sites identified in Bach2–/– cells were
not detected in WT cells, indicating that BACH2 prevents JunD binding with extremely high efficiency
at a subset of loci (Supplementary Fig. 5c-d and Supplementary Table 9). In contrast to increased
JunD binding, we observed little difference in chromatin acessibility at BACH2 binding sites in Bach2–
/– compared with WT d5 in vitro activated CD8+ T cells (Fig. 6b). Moreover, we found no correlation
between differences in JunD binding and levels of chromatin accessibility in WT and Bach2–/– cells
(Supplementary Fig. 6a). These findings indicate that in in vitro activated CD8+ T cells, BACH2
inhibits JunD binding without affecting chromatin accessibility. This behaviour is consistent with a
function of BACH2 as a passive transcriptional repressor40.
We next asked whether differences in JunD binding were associated with differences in gene
expression. We compared average differences in JunD binding at BACH2 binding sites with differences
in expression of associated genes in WT and Bach2–/– d5 in vitro activated CD8+ T cells. Increased JunD
binding in Bach2–/– cells was positively correlated with increased expression of associated genes,
especially amongst TCR-induced genes (Fig. 6c and Supplementary Table 10), as exemplified at
selected loci identified in the analysis (Figure 6d). We confirmed increased JunD binding by qPCR-
based ChIP quantification at selected loci and extended our analysis by measuring occupancy of JunB
and c-Jun, in addition to JunD, at these sites (Supplementary Fig. 6b). Increased JunD binding in
Bach2–/– cells was observed at all loci examined while increased c-Jun binding was observed at a
majority of loci and increased JunB binding was not observed. Loss of BACH2 ChIP signals in Bach2–
/– cells provides an important specificity control for the ChIP assay.
Since passive transcriptional repressors mediate their effect through competition with
transcriptional activators, their activity is often dependent upon shared DNA-binding domains with the
transcriptional activators they antagonize40. BACH2 and AP-1 TFs share possession of DNA-binding
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bZip domains. Consistent with a requisite role of the bZip domain in repression of TCR-induced genes,
BACH2-mediated inhibition of TCR-induced gene expression was abrogated when its bZip domain was
disrupted (Fig. 6e). Additionally, similar to our observations in naïve cells, excessive induction of TCR-
driven genes in Bach2–/– d5 in vitro activated cells was partially reversed upon pharmacological
inhibition of Jun activity using JNKi (Figure 6f). This led us to ask whether maintenance of CD8+ T
cell responses to acute infection is BACH2 bZip-dependent. Retroviral overexpression of BACH2
partially rescued the secondary response of d5 in vitro activated Bach2–/– OT-I cells upon transfer and
VV-OVA infection in vivo, while overexpression of Zip BACH2 failed to do so (Figure 6h).
Collectively, these results indicate that BACH2 functions as a passive repressor of TCR-driven
transcriptional programs, competitively inhibiting binding of AP-1 factors at a subset of its binding sites.
Stage-specific control of TCR-driven programs by BACH2
Given that effector differentiation proceeds in a subset of cells harboring intact Bach2 loci, we asked
whether BACH2 expression is attenuated to permit effector differentiation in a subset of cells. Analyzing
known genome-wide measurements of histone modifications in CD8+ T cells41, we noted decreased
promoter-bound H3K4me3 at the BACH2 locus in memory and effector cells compared with naïve cells
(Fig. 7a-b). Consistently, Bach2 mRNA expression was highest in naïve OT-I CD8+ T cells and was
progressively downregulated in central memory (CD62L+ KLRG1–), effector (CD62L– KLRG1–) and
terminally differentiated effector (CD62L– KLRG1+) cells 21 days following infection (Fig. 7c). We
observed corresponding changes in expression of Bach2 mRNA and the encoded protein in bulk
populations of CD8+ T cells at serial timepoints following infection, with early decreased expression at
days 5 and 7, when effector cells predominate, followed by increased mRNA expression at day 30, when
memory cells recrudesce (Supplementary Fig. 7). Thus, expression of Bach2 mRNA is dynamically
regulated in CD8+ T cells at distinct stages of differentiation.
We next asked whether modulation of Bach2 expression enables stage-specific control of its
function. CD62L– KLRG1– cells isolated at day 7 post-infection (d7 Eff) express much lower levels of
Bach2 mRNA and the encoded protein than naïve cells (Fig. 7d). Both WT and Bach2–/– d7 Eff cells are
present in sufficient numbers for transcriptional analysis. We hypothesized that the effect of Bach2
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deficiency would be less substantial in d7 Eff cells than in naïve cells corresponding to its lower
expression. To test this, we compared TCR-induced gene expression in WT and Bach2–/– naïve and d7
Eff cells using RNA-Seq. We identified TCR-driven genes that were upregulated in Bach2–/– naïve cells
compared with WT cells at either 0h or 6h following stimulation (Fig. 7e). We then compared TCR-
induced expression of these genes in WT and Bach2–/– naïve and d7 Eff cells (Fig 7f-g and
Supplementary Table 11). Strikingly, a vast majority of genes differentially expressed in naïve cells
were not significantly differentially expressed between WT and Bach2–/– cells at either 0h or 6h
following stimulation in d7 Eff cells, coinciding with reduced BACH2 expression in this subset (Fig.
7f-g). Thus, dynamic regulation of BACH2 allows for stage-specific control of TCR-driven
transcriptional programs.
Contextual control of BACH2 function by phosphorylation
Incomplete extinguishment of Bach2 mRNA in KLRG1+ terminally differentiated CD8+ T cells
prompted us to explore whether BACH2 is post-translationally modified enabling further contextual
control of its function. We noted decreased mobility of BACH2 upon denaturing gel electrophoresis of
lysates from cells that were briefly restimulated with anti-CD3 which was reversed upon treatment with
lambda phosphatase (Fig. 8a). This suggested that BACH2 is phosphorylated upon TCR stimulation. A
highly conserved serine residue at position 520 (Ser520) of murine BACH2 corresponds to a previously
reported phosphoresidue of human BACH2 in chronic myeloid leukemia cell lines (Fig. 8b)42. The
residues surrounding Ser520 form a consensus motif of the serine/threonine kinase Akt. To test whether
BACH2 Ser520 is phosphorylated by Akt following TCR stimulation, we transduced CD8+ T cells with
retroviruses encoding WT or mutant BACH2(S520A) following primary stimulation in vitro. Four days
post-transduction, cells were restimulated by crosslinking surface-bound anti-CD3 monoclonal
antibodies. Using a previously described Akt-substrate motif-specific antibody which detects RXXp[S],
we tested whether inhibition of Akt using a well-characterized and highly-specific allosteric Akt
inhibitor (Akti)43 prevents acute phosphorylation of BACH2 Ser520. Indeed, pharmacological inhibition
of Akt prevented acute phosphorylation of BACH2 whereas inhibition of downstream mTORC1
activation with rapamycin failed to inhibit this event (Fig. 8c). Moreover, S520A substitution prevented
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detectable phosphorylation. Thus, Ser520 phosphorylation of BACH2 following stimulation of CD8+ T
cells is prevented by pharmacological inhibition of Akt.
This observation led us to ask whether BACH2 is a direct substrate of Akt. We performed an in
vitro kinase reaction, combining purified Akt1 and BACH2 in the presence of adenosine triphosphate
(ATP) in vitro. Addition of purified Akt in the presence of ATP caused phosphorylation of BACH2 in
a Ser520-dependent fashion (Fig. 8d). Thus, BACH2 Ser520 is a substrate of Akt kinase in vitro. Since
Akt drives effector differentiation in CD8+ T cells44-46 and since effector differentiation is antagonized
by its substrate BACH2, we hypothesized that phosphorylation of BACH2 promotes its functional
inactivation, enabling effector differentiation to proceed. This was supported by the observation that Akt
inhibition suppresses effector differentiation in a partially BACH2-dependent manner (Supplementary
Fig. 8). To test whether Ser520 phosphorylation functionally inactivates BACH2, we overexpressed
BACH2 or BACH2(S520A) in CD8+ T cells stimulated in vitro in the presence of IL-2 and IL-12.
Despite gating on cells expressing similar amounts of the transduction marker Thy-1.1, we noted
enhanced suppression of effector cytokines and cell size when BACH2(S520A) was overexpressed (Fig.
8e). Strongly activating in vitro stimulation conditions were used since overexpression of WT BACH2
caused near-complete suppression of effector cytokines following transfer in vivo (Fig. 3b) precluding
assessment of a gain-of-function phenotype using this experimental system.
Phosphorylation of human BACH2 at a homologous residue to murine BACH2 Ser520 in chronic
myeloid leukemia cells leads to its functional inactivation through nuclear exclusion42. To test whether
phosphorylation of BACH2 causes its nuclear exclusion in T cells, CD8+ T cells were transduced with
retroviral vectors expressing BACH2-GFP and BACH2(S520A)-GFP fusion proteins the subcellular
localization of GFP within transduced (Thy-1.1+) cells was resolved following brief restimulation using
imaging flow cytometry to allow for unbiased quantification of nuclear and cytoplasmic localization.
WT BACH2 exhibited decreased nuclear localization compared with BACH2(S520A) (Fig. 8f-g)
indicating that phosphorylation of BACH2 at Ser520 favors its nuclear exclusion in CD8+ T cells.
Phosphorylation provides a mechanism by which the function of BACH2 is modulated by extrinsic
signals to enable contextual control of CD8+ T cell differentiation.
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Discussion
In this study, we have found a cell-autonomous role for BACH2 in regulating CD8+ T cell differentiation
and function following primary and secondary infection in vivo. BACH2 restrains terminal effector
differentiation and apoptosis within a subset of cells responding to viral infection allowing for generation
of long-lived memory cells that mediate secondary protection upon pathogen reencounter. BACH2 is
recruited to enhancers where it binds to AP-1 sites and modulates their availability to Jun family signal-
dependent transcription factors. In less differentiated cells, this allows BACH2 to prevent TCR-driven
induction of genes associated with terminal differentiation while in effector cells, reduction in Bach2
mRNA expression and phosphorylation of the encoded protein permit TCR driven induction of effector
cell transcriptional programmes.
The localized function of BACH2 in modulating availability of enhancers to AP-1 factors is
characteristic of short-range repression, whereby local regulation of distinct enhancers permits multiple
enhancers to function autonomously within a promoter47. This function is compatible with the
requirement for complex regulation of genes involved in lymphocyte differentiation. The observation in
activated cells that BACH2 modulates binding of Jun factors without affecting chromatin accessibility
is consistent with a model whereby BACH2 engages in passive transcriptional repression by competing
with AP-1 factors for DNA binding. A capacity for BACH2 to repress AP-1-driven transcription without
modulating chromatin structure is consistent with previous observations that BACH2 exerts chromatin
independent repression of TPA-induced reporter gene expression driven by non-chromatinized MARE
sequences48. These results do not however exclude that BACH2 may modulate chromatin structure in
other cell types or in different CD8+ T cell differentiation states. It is notable that only a subset of TCR-
induced gene loci strongly contributed to the correlation between differences in JunD binding and gene
expression in Bach2–/– and WT cells. These findings suggest that the extent of BACH2/AP-1 factor
competition or its effect on gene transcription may vary in a site-specific fashion. It is an important area
of future investigation to dissect the molecular mechanisms and sequence-level determinants for site-
specific regulation of BACH2 function.
We found that reduced transcription of the Bach2 gene in effector cells corresponded to a
decrease in its ability to restrain TCR-induced gene expression, enabling stage-dependent control of its
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function. BACH2 was also post-translationally modified to enable further contextual regulation of its
function. Our finding that Ser520 phosphorylation of BACH2 results in its functional inactivation are
consistent with previous observations in chronic myeloid leukemia cells that phosphorylation at a
homologous residue in human BACH2 causes nuclear exclusion and functional inactivation42. Future
investigations will be required to test whether modulation of BACH2 expression with progressive
differentiation and its nuclear exclusion result in differential BACH2/AP-1 competition. In our analysis,
we used TCR stimulation as an experimental system to study BACH2 phosphorylation. However, the
finding that BACH2 is phosphorylated by Akt provides a potential mechanism by which lymphocyte
differentiation is modulated by a variety of extrinsic cues. The PI3K/Akt pathway integrates diverse
antigenic, inflammatory, costimulatory and metabolic signals and regulate multiple aspects of
lymphocyte biology45, 46, 49, 50. It is an important area of future investigation to determine the range of
signals that regulate immune function by causing phosphorylation of BACH2. Additionally, it will be
important to investigate how phosphorylation affects BACH2 function at endogenous levels of
expression.
Collectively, we have found that BACH2 regulates transcriptional responses of CD8+ T cells to
TCR signaling, enabling appropriate control of CD8+ T cell responses to viral infection. Our findings
provide a basis for further investigation into how BACH2 controls the differentiation and function of
CD8+ T cells and other lymphocyte lineages. Additionally, our results identify a new target for
therapeutic manipulation of lymphocyte function in the context of chronic infections, autoimmunity and
cancer.
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Figure Legends
Figure 1. Non-redundant cell-autonomous role of BACH2 in primary and secondary CD8+ T cell
responses in vivo. a, Pre-transfer flow cytometry of WT and Bach2 KO naïve OT-I cells FACS sorted
from mixed BM chimeric mice and mixed at ~1:1 ratio. b-c, Kinetic analysis of cells in a following
transfer into recipient mice and infection with VV-OVA. Representative flow cytometry (b) and
replicate measurements (c) are shown. d, Ratio of WT and Bach2 KO CD8+ T cells in indicated organs
at day 21 following infection normalized to the ratio found in the spleen. e, Bacterial titers in livers
following infection with Listeria monocytogenes expressing OVA257-264 (LM-OVA) of animals which
were previously administered individual transfers of naïve WT or Bach2 KO OT-I cells and infected
with VV-OVA. Primary infection with VV-OVA occurred 60 days prior to secondary infection with
LM-OVA. f-g, Secondary recall responses mediated by CD44+ CD62L– effector memory (f) or CD44+
CD62L+ central memory (g) cells measured at indicated timepoints following 1:1 mixed transfer of WT
and Bach2 KO effector or central memory OT-I cells isolated at day 14 following primary infection as
in c. Numbers in gates indicate percentages. Data are representative of 2 independent experiments (c-g;
mean and s.e.m. *P<0.05; **P<0.01; ***P<0.005; ****P<0.001.
Figure 2. BACH2 prevents terminal differentiation in a subset of cells with memory
characteristics. a-d, Surface phenotype of cells before (a) or at indicated timepoints (b) following
mixed transfer of naïve WT and Bach2 KO OT-I CD8+ T cells into recipient mice and infection with
VV-OVA. Representative flow cytometry (a-b) and replicate measurements of CD62L (c) and KLRG1
(d) on the surface of transferred cells are shown. Too few KO cells were detected at day 90 for
phenotypic analysis. e, Intracellular cytokine staining of IFN- expression by WT and Bach2 KO CD8+
T cells from spleens of animals at day 5 post-infection. f, Overexpression of BACH2 prevents terminal
effector differentiation following secondary responses to infection in vivo. Expression of CD62L, CD44
and KLRG1 on the surface of CD8+ T cells 5 days following transfer of FACS-sorted GFP+ (transduced)
OT-I CD8+ T cells transduced with indicated retroviruses into animals infected with VV-OVA. g,
Expression of IFN- and TNF by transferred cells following brief restimulation ex vivo. Numbers in
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gates indicate percentages. Data are representative of 2 independent experiments (c-g; mean and s.e.m.
*P<0.05; **P<0.01; ***P<0.005; ****P<0.001.
Figure 3. BACH2 suppresses differentiation of short-lived effector cells (SLEC) and apoptosis
during acute CD8+ T cell responses to viral infection. a, Expression of CD127 and KLRG1 on the
surface of OT-I cells at day 7 following mixed transfer of naïve FACS-sorted WT and Bach2 KO OT-I
CD8+ T cells into recipient mice and infection with VV-OVA. b, BrdU incorporation by WT and Bach2
KO CD8+ T cells at the indicated timepoints following infection. Mice were injected intraperitoneally
with BrdU 16 h preceeding harvest at each timepoint. c, Annexin V and propidium iodide staining of
cells at indicated timepoints following infection. Numbers in gates indicate percentages. Data are
representative of 2 independent experiments (a-c; mean and s.e.m. *P<0.05; **P<0.01; ***P<0.005;
****P<0.001.
Figure 4. Enrichment of BACH2 at AP-1 sites within CD8+ T cell genomes. a, Relationship of
genome-wide BACH2 binding sites in d5 in vitro activated CD8+ T cells to annotated genes. b,
Consensus motif enriched within BACH2 binding sites in CD8+ T cells (left). AP-1 consensus motif
(JASPAR; right). c, Genome-wide co-localization analysis of BACH2 with indicated enhancer
associated post-transcriptional histone modifications or p300 within d5 in vitro activated CD8+ T cells.
d-f, Co-localization of JunB (d), c-Jun (e) and JunD (f) at genome-wide BACH2 binding sites in CD8+
T cells. Histograms indicate normalized average tag density at indicated distances from BACH2 peak
summits. Pie charts indicate proportions of Jun binding sites that directly overlap with BACH2 binding
sites (red indicates proportion of Jun sites exhibiting co-localization with BACH2). Binomial tests were
used to determine peak significance within ChIP-Seq data and a threshold of p<1 × 10-5 was used for
peak calling.
Figure 5. BACH2 represses TCR-driven transcriptional programs in CD8+ T cells. Naïve CD8+ T
cells were isolated and subjected to brief ex vivo stimulation with platebound anti-CD3 and anti-CD28.
a, Pie chart showing genes upregulated in Bach2–/– (KO) cells at 0, 6 or 18h (p<0.05, log2 FC>1). Of
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these genes, 192 TCR-induced genes upregulated at either 6h or 18h after stimulation in either WT or
KO cells were identified. b, Hierarchical cluster analysis of TCR-induced genes upregulated in KO cells.
Heatmap reflects average FPKM values of 2 replicate measurements normalized to row maxima. TCR-
inducibility in WT and KO cells and BACH2 binding are indicated to right of heatmap. c, Fraction of
genes in b differentially expressed in KO compared with WT cells at 0, 6 and 18h (p<0.05, log2 FC>1).
d, GESA of genes in b with transcriptional differences between terminally differentiated KLRG-1+ OT-
I cells and naïve cells. Normalized enrichment score (NES) = 1.9; Q<0.0001. e, Alignments showing
stimulation-induced mRNA expression in WT and KO naïve CD8+ T cells (top) and mapped BACH2,
JunD and H3K4me1 binding sites (bottom). f, Naïve WT and KO CD8+ T cells pretreated for 1 hr with
JNKi (12.5M) or vehicle at 37C were stimulated with platebound anti-CD3 and anti-CD28 and mRNA
expression was measured relative to Actb. g, mRNA expression at indicated timepoints following
restimulation with platebound anti-CD3 of GFP+ (transduced) cells infected with indicated retroviruses
during primary stimulation. Data are representative of 2 independent experiments (f-g; mean and s.e.m.
**P<0.01; ****P<0.001.
Figure 6. BACH2 restricts access of Jun family TFs to regulatory elements of TCR-induced genes.
a, Histogram of JunD enrichment centered around genome-wide BACH2 binding sites in WT and
Bach2–/– (KO) d5 in vitro activated CD8+ T cells. Western blot shows abundance of indicated total
proteins in these cells. b, Average ATAC-Seq signal around BACH2 binding sites in WT and KO d5 in
vitro activated CD8+ T cells. c, Scatterplot comparing differences in average JunD binding at BACH2
binding sites (x-axis) with differences in mRNA expression of associated genes (y-axis). TCR-induced
and non-induced genes are shown separately. Statistical significance was evaluated using two-sample
Kolmogorov-Smirnov test. d, Representative alignments of ChIP-, ATAC- and RNA-Seq measurements
in d5 in vitro activated CD8+ T cells at selected loci identified in c. Arrows indicate increased JunD
binding at BACH2 binding sites in Bach2–/– cells. e, mRNA expression at specific timepoints following
restimulation of transduced (GFP+) d5 in vitro activated CD8+ T cells infected with indicated
retroviruses during primary stimulation. f, mRNA expression in WT and KO CD8+ T stimulated in vitro
for 5 days in the presence of JNKi (12.5M) or vehicle. g, Congenically distinct GFP+ (transduced) WT
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and KO OT-I cells infected with indicated retroviruses during primary stimulation were cotransferred at
~1:1 ratio into recipient mice. KO/WT ratios within spleens of recipient animals were measured 5 days
after infection with VV-OVA. Data are representative of 2 independent experiments (e-f, g; mean and
s.e.m. **P<0.01; ****P<0.001).
Figure 7. Dynamic regulation of BACH2 expression enables stage-specific control of TCR-driven
gene expression. a-b, Genomic alignments (a) and quantification (b) of known H3K4me3 distribution
in naïve, memory and effector CD8+ T cells overlying the Bach2 gene (UCSC). c, Expression of Bach2
mRNA in indicated subsets of OT-I cells sorted 30 days after infection with VV-OVA. d, Bach2 mRNA
expression normalized to Actb (left), and expression of BACH2 and -actin protein levels (right) in
naïve and CD62L– KLRG1– effector OT-I cells isolated 7 days after infection with VV-OVA (d7 Eff).
e, Comparison of TCR-induced gene expression in KO and WT naïve and d7 Eff cells. Sorted naïve and
d7 Eff cells were subjected to brief (6h) stimulation ex vivo with platebound anti-CD3 and anti-CD28.
TCR-induced genes (induced by 6 h stimulation of either naïve WT (blue arc) or KO cells (red arc);
p<0.05, log2 FC>1) significantly upregulated in KO compared with WT cells at either 0 or 6 h (p<0.05,
log2 FC>1) were selected for further analysis. f, Comparison of expression of genes in e in Naïve and
d7 Eff cells at 0 or 6 h after stimulation. Heatmap shows average FPKM values of 2 replicate
measurements normalized to row maxima. g, Fraction of genes in f that are significantly differentially
expressed between KO and WT cells at either 0 or 6h following stimulation (p<0.05, log2 FC>1). Data
are representative of 2 independent experiments (c-d; mean and s.e.m. *P<0.05; **P<0.01;
****P<0.001.
Figure 8. BACH2 phosphorylation at Ser520 results in functional inactivation. a, d5 in vitro
activated CD8+ T cells were restimulated for 30 minutes with crosslinked anti-CD3 and cellular lysates
were treated with or without lambda phosphatase (LP). BACH2 migration was resolved by
immunostaining. b, Alignment of BACH2 amino acid sequences with homologous regions in other
animals. S520A mutant BACH2 is shown. c, CD8+ T cells were transduced with indicated retroviruses
during primary stimulation and restimulated with crosslinked anti-CD3 at day 4 after transduction,
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preincubating with indicated pharmacological inhibitors for 1 h. -Flag-immunoprecipitated proteins or
total lysates were subjected to immunostaining. Phospho-BACH2 was detected using an RXXpS
phospho-Akt substrate motif-specific antibody. d, Purified Akt1 was combined with ATP and
immunoprecipitated Flag-tagged WT or BACH2(S520A). Phospho-BACH2 was detected using an
RXXpS phospho-Akt substrate motif-specific antibody. e, CD8+ T cells were transduced with indicated
retroviruses during primary stimulation in rhIL-2 and IL-12 prior to restimulation on anti-CD3-coated
plates in the presence of Brefeldin A for intracellular cytokine staining. f-g, CD8+ T cells were
transduced with indicated retroviruses and cultured as in e. Cells were briefly restimulated with
platebound -CD3 (2h) and stained for the retroviral transduction marker (Thy-1.1) during the last 30
mins of culture. Fixed cells were stained with DAPI and localization of BACH2-GFP was resolved by
imaging flow cytometry. Representative cells (f) and the ratio of nuclear/cytoplasmic mean pixel
intensity (MPI) in replicate cells (g) are shown. Data are representative of 2 independent experiments
(e-g; mean and s.e.m. *P<0.05; **P<0.01; ***P<0.005.
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Online Methods
Mice and reagents.
Experiments were approved by the Institutional Animal Care and Use Committee of the NCI and were
performed in accordance with NIH guidelines. C57BL/6J, OT-I transgenic, Ly5.1+/+ and Thy-1.1+/+ mice
were purchased from The Jackson Laboratory. Bach2–/– mice, which have been previously described24,
were backcrossed >16 times with C57BL/6 mice. 8-12 week old female mice were used for experiments
unless otherwise specified. To obtain naïve WT and Bach2–/– cells, CD62L+ CD44–CD8+ T cells were
isolated by flow cytometric sorting from spleens and lymph nodes of mixed BM chimeric animals 6-12
weeks following reconstitution. WT and Bach2–/– cell compartments were distinguished from
endogenous host cells using the CD45.1 and Thy-1.1 congenic markers, respectively. Naïve CD8+ T
cells were activated with plate-bound anti-CD3 (2C11; 1 g/ml; eBioscience) and soluble anti-CD28
(37.51; 1 g/ml; eBioscience) in media containing 100 IU recombinant human IL-2 for 5 days. Where
indicated, AKTi was added to culture media at a concentration of 1 M (AKT inhibitor VIII,
Calbiochem) or JNKi at a concentration of 12.5 M (JNK Inhibitor I, (L)-Form, Calbiochem).
Viral infection and kinetic analysis.
For experiments assessing the response of CD8+ T cells to acute viral infection, 2 × 104 congenically
distinct WT or Bach2 KO naïve CD44- CD62L+ OT-I CD8+ T cells were transferred into recipient mice.
Immediately following transfer, mice were infected with 1 × 106 PFU VV-OVA. Naïve cells for transfer
were isolated by flow cytometry from mice reconstituted with 1:1 mixtures of BM from WT CD45.1+
and Bach2 KO Thy-1.1+ OT-I TCR-transgenic mice. Where indicated, WT and Bach2 KO naïve cells
were mixed at a 1:1 ratio prior to transfer.
Retroviral transduction.
pMIG- and pMIT-BACH2 constructs have been described previously23, 25. S520A substitution mutations
were generated by site-directed mutagenesis (Agilent). pMIT-BACH2-GFP and BACH2(S520A)-GFP
were generated by cloning synthesized BACH2-GFP and BACH2(S520A)-GFP fusion constructs into
the NotI and ClaI restriction sites within pMIT. Platinum-E ecotropic packaging cells (Cell Biolabs)
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were plated one day prior to transfections on poly-D-lysine coated 10-cm plates (Becton Dickinson) at
a concentration of 6 × 106 cells per plate. Packaging cells were transfected with 20 g of retroviral
plasmid DNA along with 6 g pCL-Eco plasmid DNA using 60 l Lipofectamine 2000 in 3 ml
OptiMEM (Invitrogen) for 8 h in antibiotic-free media. Media was replaced 8 h after transfection and
cells were incubated for a further 48 h. Retroviral supernatants were collected and spun at 2000g for 2
h at 32 °C onto 24-well non-tissue culture treated plates coated overnight in Retronectin (20 g/ml;
Takara Bio) and 1 g/ml anti-CD3 (2C11) and 1 g/ml anti-CD28 (37.51) (eBioscience). Cells were
cultured with 100 IU recombinant human IL-2. For experiments involving functional assessment and
subcellular localization of BACH2(S520A), media was additionally supplemented with 0.2-20 ng/ml
IL-12 (Peprotech).
Imaging flow cytometric detection of BACH2 subcellular localization.
Total CD8+ T cells were isolated by negative magnetic selection (Miltenyi), stimulated using plates
coated overnight with 1 g/ml anti-CD3 (2C11) and 1 g/ml anti-CD28 (37.51) in the presence of 100
IU IL-2 and 0.2-20 ng/ml IL-12 and transduced as described above with either pMIT-BACH2-GFP or
pMIT-BACH2(S520A)-GFP. Four days post-transduction, cells were briefly restimulated using plates
coated with 1 g/ml anti-CD3, stained with Thy-1.1-APC during the last 30 min of culture, fixed using
2% PFA in PBS, stained with 4',6-diamidino-2-phenylindole (DAPI) and analyzed using an Amnis
ImageStreamX MKII imaging flow cytometer. Data was analyzed using Amnis IDEAS. Briefly, single
cells were selected based on cell size and focus attributes, and Thy-1.1, GFP and DAPI positivity.
Cellular masks were defined as bounded by the Thy-1.1-APC cytoplasmic membrane signal, nuclear
masks were defined using the DAPI signal, and a cytoplasmic mask was defined by subtracting the
nuclear mask from the cytoplasmic mask. Mean pixel intensity of the BACH2-GFP signal was computed
within the nuclear and cytoplasmic masks separately, and the ratio of the two values were analyzed to
assess nuclear localization.
Antibodies and flow cytometry.
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The following fluorophore-conjugated antibodies against surface and intracellular antigens were used at
0.25-1×10–3 mg/ml: anti-Thy-1.1 (OX-7), anti-CD45.1 (A20), anti-KLRG1 (2F1), anti-CD25 (PC61),
anti-CD62L (MEL-14), anti-IFN- (XMG1.2), anti-TNF (MP6-XT22), anti-CD44 (IM7), and anti-
CD8 clone 53-6.7 (BD Biosciences). Cells were incubated with specific antibodies for 30 min on ice
in the presence of 2.4G2 mAb to block FcR binding. All samples were acquired with a FACS Canto II
flow cytometer (Becton Dickinson) and analyzed using FlowJo software (TreeStar). To determine
cytokine expression, cellular suspensions containing T cells were stimulated with phorbol 12-myristate
13-acetate (PMA), ionomycin and brefeldin-A (Leukocyte activation cocktail with Golgiplug; BD
Biosciences) for 4 h. After stimulation, cells were stained an amine-reactive exclusion-based viability
dye (Invitrogen) and antibodies against cell-surface antigens, fixed and permeabilized and intracellularly
stained with specific anti-cytokine antibodies. Intranuclear staining for cytokines was carried out using
the Foxp3 staining kit (eBioscience). Countbright beads (Invitrogen) were added for the flow cytometric
quantification of absolute cell number.
Immunoblotting and immunoprecipitation.
CD8+ T cells and 293T cells were lysed in IP lysis buffer (Pierce). For immunoprecipitation experiments
Flag-BACH2/BACH2(S520A) was immunoprecipitated following overnight incubation with M-2 anti-
Flag monoclonal antibodies (Sigma) using protein A/G magnetic beads (Dynal). After several washes,
immunoprecipitated proteins were released from beads using competitive elution with Flag peptide
according to manufacturer’s instructions (Sigma) or by boiling in 1x Laemmli buffer. Proteins similarly
immunoprecipitated from 293T cells and transfected with WT or BACH2(S520A) were subjected to
kinase assays while bound to beads and in the presence of ATP (Sigma) and 1x kinase buffer according
to manufacturer’s instructions (Cell Signaling).
Quantitative reverse-transcription polymerase chain reaction (qRT-PCR).
Cells were isolated by flow cytometric sorting or harvested from cell cultures and transferred into
RNALater solution (Ambion) for storage at -80 °C. Total RNA from pelleted cells was isolated using
the RNAeasy mini kit (Qiagen). First-strand cDNA synthesis was performed using random priming
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using the high-capacity cDNA synthesis kit (Applied Biosystems) in the presence of SuperaseIn RNase
inhibitor (Ambion). cDNA was used as a template for quantitative PCR reactions using Taqman primer-
probes against specified mRNA transcripts (Applied Biosystems). Reactions were performed using Fast
Universal PCR Mastermix (Applied Biosystems) and thermocycled in quadruplicate 10 l reactions in
384-well plates. Signals in the FAM channel were normalized to ROX intensity, and ct values were
calculated using automatically determined threshold values using SDS software (Applied Biosystems).
Bone marrow chimera experiments and measurement of anti-viral response kinetics.
For BM reconstitution experiments, C57BL/6 mice were administered 1000 Gy total-body -radiation
from a 137Cs source prior to intravenous injection of BM cells with or without depletion of mature
lineages from single-cell BM preparations from 6-10 week-old mice using antibody-coupled magnetic
beads (Miltenyi Biotec). To measure antiviral responses, 2 × 104 OT-I cells were transferred i.v. into
recipients prior to infection with 1 × 106 plaque-forming units VV-OVA. Where indicated, WT and
Bach2 KO naïve cells were sorted from mixed bone marrow chimeric mice and mixed at a 1:1 ratio prior
to transfer.
In vivo BrdU labeling.
For analysis of cellular proliferation in vivo, mice were administered 2 mg BrdU suspended in 500 l
PBS at 16 h (anti-viral kinetic experiment) or every day for 5 d (steady state proliferation in mixed BM
chimeras) prior to analysis. Incorporated BrdU was detected using the APC BrdU staining kit (BD
Biosciences).
RNA Sequencing and analysis.
All RNA-Seq analyses were performed using ≥2 biological replicates. Raw data from replicate 
measurements are publically available from the GEO repository. RNA sequencing was performed and
analyzed as described previously23. Briefly, total RNA was prepared from cells using the RNeasy Plus
Mini kit (Qiagen). 200 ng of total RNA was subsequently used to prepare RNA-Seq library by using
TruSeq RNA sample prep kit (FC-122-1001, Illumina) according to manufacturer’s instructions.
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Sequenced reads were aligned to the mouse genome (NCBI37/mm9) with Tophat 2.0.1151 and uniquely
mapped reads were used to calculate gene expression. RefSeq gene database (mm9) was downloaded
from the UCSC genome browser for RNA-Seq analysis. Raw counts that fell on exons of each gene
were calculated and differentially expressed genes were identified with the statistical R package edgeR52
or Cuffdiff53. Fisher’s exact test or the t-test were used to evaluate significance with indicated P-value
and fold-change thresholds. The expression heat maps were generated with the R package “pheatmap”.
Chromatin immunoprecipitation and accessibility assays
T cells were chemically crosslinked and sonicated cells to generate fragmented genomic DNA.
Chromatin immunoprecipitation was performed using the following antibodies: anti-BACH2 (N-2;
Tohoku University), anti-JunD (sc-74), anti-c-Jun (sc-45), anti-JunB (sc-73) and anti-p300 (sc-586;
Santa Cruz) anti-H3K4me1 (ab8895) and anti-H3K27Ac (ab4729; Abcam). For PCR-based
confirmation of BACH2 binding, chromatin immunoprecipitation was performed as described above,
and qPCR reactions were carried out on input and immunoprecipitated DNA using the Power SYBR
Green kit (Applied Biosystems). Genome-wide measurement of chromatin accessibility and
computational alignment of generated data were performed using ATAC-Seq on 50,000 d5 in vitro
activated CD8+ T cells as previously described54. Subsequent bioinformatic analyses were performed as
described below.
ChIP-Seq analysis
For sequencing of immunoprecipitated DNA, DNA fragments were blunt-end ligated to Illumina
adaptors, amplified, and sequenced by using the HiSeq 2000 platform (Illumina). Sequenced reads of
50–125bp were obtained by using the Illumina Pipeline. Sequenced reads were aligned to the mouse
genome (NCBI37/mm9) with Bowtie 0.12.955; only uniquely mapped reads were retained. The output
of Bowtie was converted to .bam files, which represent the genomic coordinates of each read. Reads
were mapped into non-overlapping 10-bp windows, and the location of reads on positive (negative)
strand was shifted ± 75 bp from its 5′ start to determine the approximate center of the DNA fragment 
associated with the reads. Genomic graphs were generated and viewed using the IGV (Integrative
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Genomics Viewer)56, and we aligned the BACH2, JunD, cJun, p300, H3K4me1, H3K27Ac and input
control in CD8+ T cells.
Peak calling, motif discovery and genome-wide distribution analysis
ChIP-Seq and ATAC-Seq experiments were performed to identify TF binding sites and accessible
chromatin in mouse CD8+ T cells. We used MACS 1.4.257 to call binding sites (peaks) relative to an
input control library. The binomial distribution test was used to assess peak significance and a P-value
threshold of 1 × 10-5 was used. For motif discovery, the most significant 1,000 peaks ranked by lowest
P-values were used. We extracted 100 bp of DNA sequence centered on each peak summit, and 
performed de novo motif analysis using MEME to characterize the BACH2 consensus binding motifs
in mouse CD8+ T cells. The discovered motifs were compared with JASPAR motif database to evaluate
motif similarities. 5′ UTR, 3′ UTR, introns, exons and intergenic regions were defined according to the 
RefSeq database. Peaks associated with genes (within a region 15 kb upstream of the transcription start 
site (TSS) to 3 kb downstream of the transcription end site (TES) were evaluated. The distance between 
summits of two peaks were calculated and plotted as histograms using the R package.
Genome-wide binding profiles
The genome-wide binding distribution and profile were assessed by counting the reads into binned
windows (20 bp/bin) near the binding summits. The normalized read density were then plotted in the
range of [-1 kb, 1 kb] centered on peak summits. Kolmogorov–Smirnov test was used to evaluate the
significance between two distributions.
Statistical testing
Unless otherwise specified, statistical tests were performed using unpaired two-tailed Student’s t-tests.
Where necessary, the Shapiro-Wilk test was used to test for normality of the underlying sample
distribution. No blinding was necessary since quantitative assays not subject to investigator bias were
used. Exclusion criteria were not applied. Experimental sample sizes were chosen using Power
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calculations using preliminary experiments or were based on previous experience of variability in similar
experiments. Recipient mice were randomized prior to adoptive transfer.
Methods References
51. Kim, D. & Salzberg, S.L. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts.
Genome biology 12, R72 (2011).
52. Robinson, M.D., McCarthy, D.J. & Smyth, G.K. edgeR: a Bioconductor package for differential
expression analysis of digital gene expression data. Bioinformatics 26, 139-140 (2010).
53. Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments
with TopHat and Cufflinks. Nature protocols 7, 562-578 (2012).
54. Buenrostro, J.D., Giresi, P.G., Zaba, L.C., Chang, H.Y. & Greenleaf, W.J. Transposition of
native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins
and nucleosome position. Nature methods 10, 1213-1218 (2013).
55. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S.L. Ultrafast and memory-efficient alignment
of short DNA sequences to the human genome. Genome biology 10, R25 (2009).
56. Robinson, J.T. et al. Integrative genomics viewer. Nature biotechnology 29, 24-26 (2011).
57. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome biology 9, R137 (2008).
Figure 1. 
Day 5 Day 21 Day 40
20.5
11.4
14.0
1.4
6.2
0.4
CD45.1
46.0
48.6
Th
y-
1.
1
Transfer
a
CD45.1
Th
y-
1.
1
b
c
3.3
0.0
Day 90
L
M
-O
V
A
 t
it
e
r 
(l
iv
e
r)
Time after infection (d)
P
o
p
u
la
ti
o
n
 s
iz
e
 (
1
0
4
c
e
ll
s
/m
l)
0 10 20 30
0
1
2
3 **
****
***
Time after infection (d)
P
o
p
u
la
ti
o
n
 s
iz
e
 (
1
0
4
c
e
ll
s
/m
l)
0 10 20 30
0
1
2
3
*
*
****
WT
KO
WT
KO
d e
f g
0 104103102 0 105104103
0
104
103
102
105
104
103
102
0
-101
102
Figure 2. 
a
Day 5 Day 21 Day 40 Day 90Transfer
WT
(Ly5.1+)
KO
(Thy-1.1+)
14.4
5.4
27.0
1.4
24.4
2.7
8.9
19.0
17.1
8.6
12.8
25.1
9.15
54.3
CD44
CD
62
L
KLRG1
0.1
0.097.1
2.8
0.0
0.095.8
4.2
b
WT
(Ly5.1+)
KO
(Thy-1.1+)
CD
62
L
c d e
IF
N
-
+
c
e
lls
 (
%
)
IFN-γ
4.8 20.1
24.051.4
9.7 4.3
4.381.3TN
F
EV BACH2
CD62L CD44 KLRG1
Ev
e
n
ts
 
(%
 
o
f m
a
x)
f g
C
D
4
4
 M
F
I
K
L
R
G
1
+
 c
e
ll
s
 (
%
)
0
10
20
30 **
WT
IFN-γ
Ev
e
n
ts
 
(%
 
o
f m
a
x)
27.4
43.4
KO
EV
BACH2
C
D
6
2
L
+
 c
e
ll
s
 (
%
)
EV BACH2 EV BACH2 EV BACH2 EV BACH2 EV BACH2
0 105104103
105
104
103
102
0
102 0 105104103102
105
104
103
0
0 105104103102
100
80
60
40
20
0
0 105104103102 0 105104103102 0 105104103102 0 105104103102
100
80
60
40
20
0 0
105
104
103
102
Time after infection (d)
A
n
n
V
+
c
e
ll
s
 (
%
)
0 6 12 18
0
20
40
60 WT
KO
**
****
****
NS
C
D
1
2
7
+
 K
L
R
G
1
–
 c
e
ll
s
 (
%
)
KLRG1
CD
12
7
WT KO
21 1.8
9.6
1.3 0.35
30
a
Time after infection (d)
B
rd
U
+
 c
e
ll
s
 (
%
)
0 6 12 18
0
20
40
60
80
100 WT
KO
NS
*
***
***
AnnV
Pr
o
pi
di
u
m
io
di
de
Day 5 Day 7 Day 10
WT
(Ly5.1+)
KO
(Thy-1.1+)
b
78.7
71.6
35.7
28.3
9.8
9.5
Day 5 Day 7 Day 10
CD
8α
BrdU
WT
(Ly5.1+)
KO
(Thy-1.1+)
Figure 3. 
c
C
D
1
2
7
–
 K
L
R
G
1
+
 c
e
ll
s
 (
%
)
0 105104103102
0
105
104
103
102
0 105104103102
0
105
104
103
102
0 105104103102
0
105
104
103
102
8.2
25.265.6
13.7
4.979.4
13.2
7.877.3
13.2
29.156.6
25.1
5.867.0
Figure 4. 
–1000 10000 500–500
0
40
60
80
20
Distance from BACH2 to nearest 
cJun peak  
–1000 10000 500–500
0
60
80
100
40
Distance from BACH2 to nearest 
JunD peak  
20
–1000 10000 500–500
0
40
50
60
30
Distance from BACH2 to nearest 
JunB peak  
20
10
d
498
(43%) 647
(57%) 3825(70%)
1617
(30%) 1258(45%) 1511(55%)
Ta
g 
de
n
si
ty
 
(no
rm
al
ize
d)
Ta
g 
de
n
si
ty
 
(no
rm
al
ize
d)
Ta
g 
de
n
si
ty
 
(no
rm
al
ize
d)
e f
1 2 3 4 5 6 7 8 9 10 11 12
2
1
0
Bi
ts
Position in motif
AP-1 (JASPAR)
2
1
0
Bi
ts
BACH2 (CD8)
1 2 3 4 5 6 7 8 9 10 11 12
a
11
11 2
1
9
35
31
Upstream
Promoter
3´ UTR
Exon
5´ UTR
Intron
Intergenic
cb
BACH2
H3K4me1
p300
H3K27Ac
6,987
664
31,773
12,545
937
96
5732
6,861
787
2041
23
74
467
2714
2,730
Figure 5. 
0 6 18
0
50
100
Time (h)
m
R
N
A
 t
ra
n
s
cr
ip
ts
 (
%
)
Up
Down
NS
a
Up in KO naïve cells
(0, 6 or 18 h after stimulation):
TCR-induced in 
WT (104; 23%)
Not TCR-
induced
b
264;
57%
KO / WT:
TCR-induced in 
KO (175; 38%)
ed
G
p4
9a
 
m
RN
A 
(A
U) WTKO
0 0 6 6 6 6
– – – – + +
+ + + + – –
Time (h)
JNKi
Veh
0 0 6 6 6 6
– – – – + +
+ + + + – –
Ifn
g
m
RN
A 
(A
U)
gf
EV ∆Zip BACH2BACH2
Ccr4
Tnf
Socs1
Gadd45g
Irf1
Lta
Ifng
Icam1
Hmox1
Ccl3
Gadd45b
Ccl4
Cxcl10
Gp49a
Atxn1
Cd44
Socs2
Id2
Lamc2
Ttc39c
WT KO WT KO WT KO
0 h 6 h 18 h
0.0 0.6 1.00.2 0.4 0.8
Expression 
(relative) 
WT KO
TCR-
induced
BACH2-
bound
Rank in ordered data set 
(FC KLRG1+/NAI x103)
En
ric
hm
en
t s
co
re
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0.7
0.8
5.0
0.0
-5.0
-10.0
-10.0
Ra
n
ke
d 
lis
t m
et
ric
0 5 10 15 20 22.517.512.57.52.5
Positive Negative
Time after stimulation (h)
G
p4
9a
 
m
RN
A 
(A
U)
Time after stimulation (h)
Ifn
g
m
RN
A 
(A
U)
Gp49a Lilrb4 Ifng
WT 0 h
KO 0 h
WT 6 h
KO 6 h
4.8
4.8
4.8
4.8
WT
WT
4.0
3.6
6.8
0.8
32
32
32
32
WT
4.13.0
RNA-Seq
BACH2 ChIP
H3K4me1 ChIP
JunD ChIP
SampleAssay
c
Figure 6. 
cba
d
WT
Bach2–/–
WT
Bach2–/–
WT
Bach2–/–
Havcr2 Ttc39c Prdm1
18
1.8
1.8
1.7
1.7
5.4
5.4
2.4
1.3
1.3
2.1
2.1
5.8
5.8
2.8
15
2.5
2.5
4.3
4.3
0.2
0.2
3.4
24
e
WT KO
– +
+ –
– +
+ –
WT KO
– +
+ –
– +
+ –
EV ∆Zip BACH2BACH2
Ha
vc
r2
 
m
RN
A 
(A
U)
f
g
Distance from nearest BACH2 peak (bp)
0 +400 +800-800 -400
0
1.0
2.0
0.5
1.5
3.0
3.5
2.5
Ju
n
D
en
ric
hm
en
t (n
o
rm
al
ize
d 
x1
0-
8 ) Bach2–/–
WT
JunD
1.61.3JunD
BACH2
β-actin
5
4
2
1
0 +500 +1000-500-1000
AT
AC
-
Se
q
si
gn
al
 
(R
PM
/2
0 
bp
)
3
Bach2–/–
WT
Distance from nearest BACH2 peak (bp) Bach2–/–/ WT JunD binding (log2 fold) 
Ba
ch
2–
/–
/ W
T 
m
RN
A 
ex
pr
es
si
o
n
 
(lo
g 2
fo
ld
) 
Non-induced TCR-induced
0 1 1.5–1
3
2
1
0
-1
-2
–0.5 0.5
P<0.0001
WT
WT
JunD ChIP
RNA-Seq
ATAC-Seq
H3K4me1 ChIP
BACH2 ChIP
Assay Genotype
KO
 
/ W
T 
G
FP
+
ce
lls
Tt
c3
9c
 
m
RN
A 
(A
U)
Pr
dm
1 
m
RN
A 
(A
U)
Time (h) Time (h) Time (h)
JNKi
Veh
WT KO
– +
+ –
– +
+ –
Ha
vc
r2
 
m
RN
A 
(A
U)
Tt
c3
9c
 
m
RN
A 
(A
U)
Pr
dm
1 
m
RN
A 
(A
U)
Figure 7. 
B
a
c
h
2
 m
R
N
A
 (
A
U
)Nai
Mem
Eff
5
5
5
Bach2
Nai Mem Eff
0
5
10
15
ca
f
b
e g
B
a
c
h
2
m
R
N
A
 (
A
U
)
d
0.0
0.6
1.0
0.2
0.4
0.8
Expression
(relative)
Naive
WT KO WT KO
0 h 6 h
WT KO WT KO
0 h 6 h
d7 Eff
Up in KO naïve cells
(0 or 6 h after stimulation):
TCR-induced (6h) 
in WT (59; 21%)
Not TCR-
induced
181;
63% TCR-induced (6h) 
in KO (88; 30%) 0
50
100
0h 6h 0h 6h
Naive d7 Eff
Up DownNS
0 7
BACH2
β-actin
Time after
infection (d)
0.86 0.02BACH2
(kDa)
100
35
130
- - + +
- + - +
Purified Akt (1µg)
(kDa)
150
100
RXXpS (P-BACH2)
Flag (BACH2)
- - + +
- + - +ATP (200µM)
150
100
- - + -
- + + +
AKTi (1µM) (kDa)
150
100
Flag (BACH2)
- - +
-
- + + +
- - - +Rapamycin (100nM) - - - +
anti-CD3 (10min)
Flag-BACH2
Flag-
BACH2 
(S520A)
IP
(Flag)
100
50
75
P-AKT (T308)
P-S6K1 (T389)Lys
S6K1 75
150
RXXpS (P-BACH2)
a b
c
f
505 VCPRSPPLETRTRTSSSCSSYSYAEDGSGGS 535Mouse (WT)
506 VCPRSPPLETRTRTSSSCSSYSYAEDGSGGS 536Human
508 VCPRSPPLETRTRTSSSCSSYSYAEDGSGGS 538Cow
506 VCPRSPPLETRTRTSSSCSSYSYAEDGSGGS 535Rat
513 VCPRSPPLETRTRTSSSCSSYSYAEDGSGGS 543Dog
497 VCPRSPPLETRTRTSSSCSSYSYAEDGSGGS 527Frog
490 VCPRSPPLETRTRTSSSCSSYSYAEDGSGGS 520Chicken
505 VCPRSPPLETRTRTSASCSSYSYAEDGSGGS 535Mouse (S520A)
N
u
c
le
a
r 
/ 
c
y
to
p
la
s
m
ic
 G
F
P
 i
n
te
n
s
ity
e
Figure 8. 
GFP DAPI Thy1.
1
Merge GFP DAPI Thy1.
1
Merge
BACH2-GFP BACH2(S520A)-GFP
- - + +LP
- + - +anti-CD3 (30 min)
p-Bach2
Bach2
d
IF
N
-
+
 c
e
lls
 (
%
)
T
N
F
+
 c
e
lls
 (
%
)
0.8
0.9
1.0
1.1
1.2
*NS
IFN-γ
Ev
en
ts
TNF FSC
EV
BACH2
BACH2
(S520A)
EV
BACH2
BACH2
(S520A)
g
Flag-BACH2
Flag-
BACH2 
(S520A)
